Treatment cancers using a combination comprising PARP inhibitors

1. A method for the delay of progression or treatment of cancer in a subject, wherein the cancer is selected from the group consisting of colorectal cancer, gastric cancer, lung cancer, small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, fallopian tube carcinoma, cervical cancer, peritoneal carcinoma, prostate cancer, castration-resistant prostate, bile duct cancer, gastric/gastro-esophageal junction cancer, urothelial cancer, pancreatic cancer, peripheral nerve sheath cancer, uterine cancer, and melanoma, the method comprising administering to the subject in need thereof a therapeutically effective amount of a PARP inhibitor, in combination with a therapeutically effective amount of an immune checkpoint inhibitor, or a chemotherapeutic agent,

wherein the PARP inhibitor is a compound of Formula (I),

a stereoisomer thereof, or a pharmaceutically acceptable salts thereof, or a compound of Formula (III),

a pharmaceutically acceptable salt thereof, or a compound of Formula (IV),

wherein:

R N is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

X is selected from the group consisting of C, N, O, and S;

m and n, which may be the same or different, are each an integer of 0, 1, 2, or 3;

t is an integer of 0, 1, 2, or 3;

R 1 , at each occurrence, is independently selected from the group consisting of halogen, CN, NO 2 , OR 9 , NR 9 R 10 , NR 9 COR 10 , NR 9 SO 2 R 10 , CONR 9 R 10 , COOR 9 , SO 2 R 9 , alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

R 2 is selected from the group consisting of hydrogen, COR 9 , CONR 9 R 10 , CO 2 R 9 , SO 2 R 9 , alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

R 3 , R 4 , R 5 , R 6 , R 7 and R 8 , which may be the same or different, are each independently selected from the group consisting of hydrogen, halogen, —NR 9 R 10 , —OR 9 , oxo, —COR 9 , —CO 2 R 9 , —CONR 9 R 10 , —NR 9 CONR 10 R 11 , NR 9 CO 2 R 10 , —NR 9 SO 2 R 10 , —SO 2 R 9 , alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, alkynyl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ,

or (R 3 and R 4 ), and/or (R 4 and R 5 ), and/or (R 5 and R 6 ), and/or (R 6 and R 7 ), and/or (R 7 and R 8 ), together with the atom(s) they are attached, form a 3- to 8-membered saturated, partially or fully unsaturated ring having 0, 1 or 2 heteroatoms independently selected from the group consisting —NR 13 —, —O—, —S—, —SO— and —SO 2 —, and said ring is optionally substituted with at least one substituent R 12 ,

provided that

when X is O, R 5 and R 6 are absent,

when X is N, R 6 is absent,

when X is S, R 5 and R 6 are absent, or at least one of R 5 and R 6 is oxo,

when one of R 3 and R 4 is oxo, the other is absent,

when one of R 7 and R 8 is oxo, the other is absent, and

when X is C and one of R 5 and R 6 is oxo, the other is absent;

R 9 , R 10 , and R 11 , which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

R 12 is selected from the group consisting of CN, halogen, haloalkyl, NO 2 , —NR′R″, —OR′, oxo, —COR′, —CO 2 R′, —CONR′R″, —NR′CONR″R′″, —NR′CO 2 R″, —NR′SO 2 R″, —SO 2 R′, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein R′, R″, and R′″ are independently selected from the group consisting of hydrogen, haloalkyl, alkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R′ and R″), and/or (R″ and R′″) together with the atoms to which they are attached, form a 3- to 8-membered saturated, partially or fully unsaturated ring having 0, 1 or 2 additional heteroatoms independently selected from the group consisting of —NR 13 —, —O—, —S—, —SO— and —SO 2 —,

R 13 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl,

and wherein the immune checkpoint inhibitor is an antibody or fragment thereof that specifically binds to human PD-1, wherein the antibody or fragment thereof comprises a heavy chain variable region (Vh) and a light chain variable region (Vl), wherein the Vh comprises SEQ ID NO: 31(CDR1-H1), SEQ ID NO: 32(CDR2-H2), and SEQ ID NO: 33(CDR3-H3) respectively; and the Vl comprises SEQ ID NO: 34(CDR1-L1), SEQ ID NO: 35(CDR2-L2), and SEQ ID NO: 36(CDR3-L3), respectively;

and wherein the chemotherapeutic agent is paclitaxel or etopside plus carboplatin (E/C).

2. The method of claim 1 , wherein the antibody that specifically binds to human PD-1 is a monoclonal antibody.

3. The method of claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable region (Vh) amino acid sequence of SEQ ID No 24, and a light chain variable region (Vl) amino acid sequence of SEQ ID No 26.

4. The method of claim 1 , wherein the cancer is selected from the group consisting of colorectal cancer, gastric cancer, lung cancer, small cell lung cancer, breast cancer, and ovarian cancer.

5. The method of claim 1 , wherein the PARP inhibitor is the compound of Formula (III),

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the PARP inhibitor is the compound of Formula (IV),

7. The method of claim 1 , wherein the immune checkpoint inhibitor and the PARP inhibitor are administered simultaneously, sequentially or separately.

8. The method of claim 1 , wherein the PARP inhibitor is administrated orally at a dose of 1-120 mg twice daily.

9. The method of claim 1 , wherein the PARP inhibitor is administrated orally at a dose of 120-240 mg once a day.

10. The method of claim 1 , wherein the immune checkpoint inhibitor is administered parenterally at a dose of 0.5-10 mg/kg once weekly, or every two weeks, or every three weeks, or every four weeks.

11. The method of claim 1 , wherein the immune checkpoint inhibitor is administrated at a dose of 2 mg/kg every three weeks.

12. The method of claim 1 , wherein the immune checkpoint inhibitor is administrated at a dose of 2 mg/kg every three weeks (Q3W), and the PARP inhibitor is administrated at a dose of 20 mg, 40 mg or 60 mg twice daily.

13. The method of claim 1 , wherein the immune checkpoint inhibitor is administrated at a dose of 200 mg every three weeks, and the PARP inhibitor is administrated at a dose of 40 or 60 mg twice daily.

14. The method of claim 1 , wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

15. The method of claim 1 , wherein the wherein the antibody is a monoclonal antibody comprising a heavy chain variable region (Vh) amino acid sequence of SEQ ID No 24, a light chain variable region (Vl) amino acid sequence of SEQ ID No 26, and a IgG4 constant domain amino acid sequence of SEQ ID NO 88.

16. A pharmaceutical combination for use in the delay of progression or treatment of cancer, wherein the cancer is selected from the group consisting of colorectal cancer, gastric cancer, lung cancer, small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, fallopian tube carcinoma, cervical cancer, peritoneal carcinoma, prostate cancer, castration-resistant prostate, bile duct cancer, gastric/gastro-esophageal junction cancer, urothelial cancer, pancreatic cancer, peripheral nerve sheath cancer, uterine cancer, and melanoma, the pharmaceutical combination comprising a PARP inhibitor and a chemotherapeutic agent, wherein the chemotherapeutic agent is selected from the group consisting of paclitaxel and etoposide/carboplatin (E/C), and wherein the PARP inhibitor is a compound of Formula (I),

a stereoisomer thereof, or a pharmaceutically acceptable salts thereof, or a compound of Formula (III),

a pharmaceutically acceptable salt thereof or a compound of Formula (IV),

wherein:

R N is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

X is selected from the group consisting of C, N, O, and S;

m and n, which may be the same or different, are each an integer of 0, 1, 2, or 3;

t is an integer of 0, 1, 2, or 3;

R 1 , at each occurrence, is independently selected from the group consisting of halogen, CN, NO 2 , OR 9 , NR 9 R 10 , NR 9 COR 10 , NR 9 SO 2 R 10 , CONR 9 R 10 , COOR 9 , SO 2 R 9 , alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

R 2 is selected from the group consisting of hydrogen, COR 9 , CONR 9 R 10 , CO 2 R 9 , SO 2 R 9 , alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

R 3 , R 4 , R 5 , R 6 , R 7 and R 8 , which may be the same or different, are each independently selected from the group consisting of hydrogen, halogen, —NR 9 R 10 , —OR 9 , oxo, —COR 9 , —CO 2 R 9 , —CONR 9 R 10 , —NR 9 CONR 10 R 11 , —NR 9 CO 2 R 10 , —NR 9 SO 2 R 10 , —SO 2 R 9 , alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, alkynyl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ,

or (R 3 and R 4 ), and/or (R 4 and R 5 ), and/or (R 5 and R 6 ), and/or (R 6 and R 7 ), and/or (R 7 and R 8 ), together with the atom(s) they are attached, form a 3- to 8-membered saturated, partially or fully unsaturated ring having 0, 1 or 2 heteroatoms independently selected from the group consisting of —NR 13 —, —O—, —S—, —SO— and —SO 2 —, and said ring is optionally substituted with at least one substituent R 12 ,

provided that

when X is O, R 5 and R 6 are absent,

when X is N, R 6 is absent,

when X is S, R 5 and R 6 are absent, or at least one of R 5 and R 6 is oxo,

when one of R 3 and R 4 is oxo, the other is absent,

when one of R 7 and R 8 is oxo, the other is absent, and

when X is C and one of R 5 and R 6 is oxo, the other is absent;

R 9 , R 10 , and R 11 , which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

R 12 is selected from the group consisting of CN, halogen, haloalkyl, NO 2 , —NR′R″, —OR′, oxo, —COR′, —CO 2 R′, —CONR′R″, —NR′CONR″R′″, —NR′CO 2 R″, —NR′SO 2 R″, —SO 2 R′, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein R′, R″, and R′″ are independently selected from the group consisting of hydrogen, haloalkyl, alkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R′ and R″), and/or (R″ and R′″) together with the atoms to which they are attached, form a 3- to 8-membered saturated, partially or fully unsaturated ring having 0, 1 or 2 additional heteroatoms independently selected from the group consisting of —NR 13 —, —O—, —S—, —SO— and —SO 2 —,

R 13 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl.

17. A pharmaceutical combination for use in the delay of progression or treatment of cancer, wherein the cancer is selected from the group consisting of colorectal cancer, gastric cancer, lung cancer, small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, fallopian tube carcinoma, cervical cancer, peritoneal carcinoma, prostate cancer, castration-resistant prostate, bile duct cancer, gastric/gastro-esophageal junction cancer, urothelial cancer, pancreatic cancer, peripheral nerve sheath cancer, uterine cancer, and melanoma, the pharmaceutical combination comprising a PARP inhibitor, and an immune checkpoint inhibitor, wherein the PARP inhibitor is a compound of Formula (I),

a stereoisomer thereof, or a pharmaceutically acceptable salts thereof, or a compound of Formula (III),

a pharmaceutically acceptable salt thereof, or a compound of Formula (IV),

wherein:

R N is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

X is selected from the group consisting of C, N, O, and S;

m and n, which may be the same or different, are each an integer of 0, 1, 2, or 3;

t is an integer of 0, 1, 2, or 3;

R 1 , at each occurrence, is independently selected from the group consisting of halogen, CN, NO 2 , OR 9 , NR 9 R 10 , NR 9 COR 10 , NR 9 SO 2 R 10 , CONR 9 R 10 , COOR 9 , SO 2 R 9 , alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

R 2 is selected from the group consisting of hydrogen, COR 9 , CONR 9 R 10 , CO 2 R 9 , SO 2 R 9 , alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

R 3 , R 4 , R 5 , R 6 , R 7 and R 8 , which may be the same or different, are each independently selected from the group consisting of hydrogen, halogen, —NR 9 R 10 , —OR 9 , oxo, —COR 9 , —CO 2 R 9 , —CONR 9 R 10 , —NR 9 CONR 10 R 11 , —NR 9 CO 2 R 10 , —NR 9 SO 2 R 10 , —SO 2 R 9 , alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, alkynyl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ,

or (R 3 and R 4 ), and/or (R 4 and R 5 ), and/or (R 5 and R 6 ), and/or (R 6 and R 7 ), and/or (R 7 and R 8 ), together with the atom(s) they are attached, form a 3- to 8-membered saturated, partially or fully unsaturated ring having 0, 1 or 2 heteroatoms independently selected from the group consisting of —NR 13 —, —O—, —S—, —SO— and —SO 2 —, and said ring is optionally substituted with at least one substituent R 12 ,

provided that

when X is O, R 5 and R 6 are absent,

when X is N, R 6 is absent,

when X is S, R 5 and R 6 are absent, or at least one of R 5 and R 6 is oxo,

when one of R 3 and R 4 is oxo, the other is absent,

when one of R 7 and R 8 is oxo, the other is absent, and

when X is C and one of R 5 and R 6 is oxo, the other is absent;

R 9 , R 10 , and R 11 , which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently optionally substituted with at least one substituent R 12 ;

R 12 is selected from the group consisting of CN, halogen, haloalkyl, NO 2 , —NR′R″, —OR′, oxo, —COR′, —CO 2 R′, —CONR′R″, —NR′CONR″R′″, —NR′CO 2 R″, —NR′SO 2 R″, —SO 2 R′, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein R′, R″, and R′″ are independently selected from the group consisting of hydrogen, haloalkyl, alkyl, arylalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or (R′ and R″), and/or (R″ and R′″) together with the atoms to which they are attached, form a 3- to 8-membered saturated, partially or fully unsaturated ring having 0, 1 or 2 additional heteroatoms independently selected from the group consisting of —NR 13 —, —O—, —S—, —SO— and —SO 2 —,

R 13 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl,

and wherein the immune checkpoint inhibitor is an antibody or fragment thereof that specifically binds to human PD-1, wherein the antibody or fragment thereof comprises a heavy chain variable region (Vh) and a light chain variable region (Vl), wherein the Vh comprises SEQ ID NO: 31(CDR1-H1), SEQ ID NO: 32(CDR2-H2), and SEQ ID NO: 33(CDR3-H3) respectively; and the Vl comprises SEQ ID NO: 34(CDR1-L1), SEQ ID NO: 35(CDR2-L2), and SEQ ID NO: 36 (CDR3-L3), respectively.

18. The pharmaceutical combination of claim 17 , wherein the antibody that specifically binds to human PD-1 is a monoclonal antibody.

19. The pharmaceutical combination of claim 18 , wherein the antibody comprises a heavy chain variable region (Vh) amino acid sequence of SEQ ID No 24, a light chain variable region (Vl) amino acid sequence of SEQ ID No 26, and a IgG4 constant domain amino acid sequence of SEQ ID NO 88.

20. The pharmaceutical combination of claim 17 , wherein the cancer is selected from the group consisting of colorectal cancer, gastric cancer, lung cancer, small cell lung cancer, breast cancer, and ovarian cancer.

21. The pharmaceutical combination of claim 17 , wherein the PARP inhibitor is the compound of Formula (III),

or a pharmaceutically acceptable salt thereof.

22. The pharmaceutical combination of claim 17 , wherein the PARP inhibitor is the compound of Formula (IV),

23. The pharmaceutical combination of claim 16 , wherein the immune checkpoint inhibitor and the PARP inhibitor are administered simultaneously, sequentially or separately.

24. The pharmaceutical combination of claim 17 , wherein the PARP inhibitor is administrated orally at a dose of 1-120 mg twice daily.

25. The pharmaceutical combination of claim 17 , wherein the PARP inhibitor is administrated orally at a dose of 1-80 mg twice daily.

26. The pharmaceutical combination of claim 17 , wherein the anti-PD-1 antibody, which is administered parenterally at a dose of 0.5-10 mg/kg once weekly, or every two weeks, or every three weeks, or every four weeks.

27. The method of claim 1 , wherein the PARP inhibitor is administrated orally at a dose of 1-80 mg twice daily.

28. The method of claim 1 , wherein the PARP inhibitor is administrated orally at a dose of 60-120 mg once a day.

29. The pharmaceutical combination of claim 16 , wherein the PARP inhibitor is the compound of Formula (IV),